COVID-19 and Human Subjects Research Activities 

General Principles | Stage 2 | International Research | Minimum Requirements for in-person activities | Expectations of Research Participants | Health Pre-screening for Research Participants | Script for Use by Research Teams | Contact Tracing | Required Attestations | PREP Act | Frequently Asked Questions 

This webpage has been substantively updated to provide guidance to the Brown University research community regarding Stage 2 resumption of human subjects research activities on-campus at Brown, at field sites and venues off-campus, and at international research sites. It is the responsibility of Principal Investigators or their study teams to check this site regularly for updates.

General Principles for Staged Restarting of In-Person Human Subjects Research Activities

  • Brown continues to prioritize public health and the safety of faculty, staff, and students, while also maintaining our ethical obligation to protect individuals who volunteer to participate in research.
  • Plans to resume human subjects research activities that involve in-person procedures must align with all Brown policies, guidance from public health authorities and, when applicable, State of Rhode Island requirements.
  • Recognizing that the future remains uncertain, new human subjects research activities must be proposed in new IRB submissions in ways that enable the research community to be nimble and revert back to remote procedures or modified ways of conducting in-person interactions. This means that new IRB submissions must include both in-person and remote options for all procedures that involve in-person interactions with research participants, or otherwise state that a given procedure (e.g., blood draws) will only be conducted in a stage during which in-person procedures are permitted or otherwise authorized by the Office of the Vice President for Research (OVPR). Additional information regarding plans to revert to prior stages and related procedures if necessary can be found in the FAQs on this page.


General Requirements & Guidance

  • Human subjects research studies currently and successfully administering procedures using remote options are strongly encouraged to continue to do so.
  • Human subjects research studies that can be conducted remotely, but would be more effective on-site and in-person (e.g., the effect size of the intervention would be diminished if the work is conduct remotely) may be permitted with the submission and approval of a Plan. This Plan should provide a brief justification of the need for on-campus, in-person human subjects research activities. There will be a streamlined review and approval process for studies that already received approval for on-campus activities in Stage 1 and want to make changes to their Plan for Stage 2.
  • In studies where some, but not all, procedures cannot be done remotely, careful consideration should be given to minimizing in-person, on-campus visits. For example, an initial in-person visit to conduct requisite in-person procedures can also be used to train participants to self-administer study procedures at home to minimize future on-campus visits.

Special Considerations for certain On-campus Research Activities

  • Interventions conducted in groups on campus are permissible, provided groups are limited to 10 or fewer individuals, with all individuals spaced at least 6 feet apart and wearing face coverings, in spaces large enough to accommodate such groups while adhering to social distancing guidelines.
  • If approved research requires use of the MRI, Brown will provide disposable surgical-type masks to research participants undergoing the MRI that are the same, or nearly the same as, the masks it will provide to Brown researchers. Please see below for PREP Act language that must be included in consent documents when a study participant will be entering the MRI as part of a research procedure.

Off-campus Research

  • Research conducted in community settings in Rhode Island or other sites within commuting distance is permitted, provided groups are limited to 10 or fewer individuals (e.g., focus groups), investigators have permission of the facility to conduct research on-premise, and investigators conform to all requirements of the facility (e.g., use of facial coverings, social distancing, and any other enhanced safety precautions).
  • Surveys conducted outdoors in the community are permitted with mask wearing and social distancing of at least 6 feet.
  • Researchers are not permitted to enter participants’ private residences during Stage 2.

Continued Requirements from Stage 1

  • Exception requests will be considered on a study-by-study basis via a plan submitted by the Principal Investigator. Requirements for what must be in this plan and how to submit the plan can be found here. Please note that additional attestations, as described on this page are required to commence in-person human subjects research activities.
  • All research personnel must adhere to the Brown University COVID-19 Workplace Safety Policy regarding use of personal protective equipment (PPE), personal health and hygiene, disinfecting protocols, social distancing, and contact tracing, in the conduct of all on-campus human subjects research activities.
  • All on-campus human subjects research studies that are approved via an exception request/submission of a plan must abide by the Minimum requirements for in-person, on-campus human subjects research activities.
  • Implementing or enhancing cleaning and disinfecting protocols or PPE and other measures specific to minimizing transmission of COVID-19, such as health pre-screening, do not require an amendment to an IRB-approved protocol. Similarly, enhancing communications with research participants to describe precautions the study team or the research participant must take to prevent the spread of illness do not require an amendment to an IRB-approved protocol.
  • In instances where Brown has ceded oversight authority to another IRB via an IRB Authorization Agreement (IAA), Principal Investigators must complete an attestation affirming that they will adhere to the requirements of that IRB regarding protection of research participants from COVID-19 related risks.
  • If any human subjects research activities under an IAA involve in-person interactions with participants on-campus at Brown, the Principal Investigator must submit an exception request for these activities via a plan submitted to the OVPR, as noted above.
  • In instances where Brown is the IRB of Record for an external clinical site with its own IRB (in a multi-site study), and that clinical site wishes to resume in-person procedures with participants, the Brown Principal Investigator must submit written documentation to [email protected] from the clinical site's IRB affirming that the proposed in-person procedures are permissible at the clinical site. In accord with the Stage 2 resuming research requirements, all research occurring in non-Brown-controlled spaces or areas must satisfy and be performed in accordance with the state, local, and other applicable requirements and guidelines in place for the space or area where the research occurs. This includes the public health guidelines of local government(s) and policies of collaborating institutions. This research is subject to all applicable United States, University and local travel restrictions.   

International Research

  • All faculty, students, and staff must abide by Brown’s COVID-19 Travel Restrictions.
  • Researchers currently located abroad at their planned study location may resume or begin IRB/HRPP-approved in-person human subjects research activities if permitted in accordance with country-level and location-specific public health requirements. No exceptions to country requirements will be permitted (i.e., conducting biospecimen collection if social distancing is required).
  • All researchers who plan to resume or begin in-person human subjects research activities abroad must submit an International Research Attestation Form to the HRPP with the new IRB Application or IRB Amendment and receive approval prior to commencing human subjects research activities. The review and approval process may involve seeking additional information from the PI. Please note that these activities must include health and safety measures to be taken by Brown students, staff, or faculty as set forth in the attestation, including any health and safety measures (e.g., wearing a face covering) required at the international site.  
  • All researchers who receive approval to commence in-person human subjects research activities abroad must conduct a self-screen for any of the following new or worsening sings of possible COVID-19 infection before each contact with any research participant, and must not interact with research participants if exhibiting any of the following symptoms;
  1. Cough
  2. Shortness of breath or difficulty breathing
  3. Chills
  4. Sore throat
  5. New loss of taste or smell
  6. Feeling feverish or a measured temperature greater than or equal to 100 degrees Fahrenheit

*This list does not include all possible symptoms. See the CDC website for more information.

Minimum requirements for in-person, on-campus human subjects research activities

All plans submitted to OVPR requesting to resume in-person, on-campus human subjects research activities during Stage 2 must include the following minimum information:

1) Affirmation that the study team will conduct a health pre-screening with research participants prior to their study visits and another health screening when the research participant arrives for each study visit.

2) Affirmation that the study team will discuss with research participants the safety protocols implemented at Brown to reduce risk of transmission of COVID-19 prior to their study visit. This must include any Expectations of study participants.

3) Affirmation that the study team will inform research participants of the Brown University requirement that they wear a face covering during their study visit.

4) Affirmation that the study team will provide research participants with information about the Centers for Disease Control and Prevention groups determined to be at higher risk for severe illness, either verbally via a script or via an electronic method (for example, sent via email or Qualtrics). This will enable participants to make an informed decision about personal risks related to COVID-19.

5) Affirmation that if the study team will provide a face covering to a participant, including, but not limited to, participants undergoing MRI, the study team will inform that participant that Brown cannot guarantee that the facial covering will protect against the risks of COVID-19.

In addition, research teams should consider the following when scheduling research participants for on-campus study visits:

  • Through what entrance/exit will research participants be instructed to access the building?
  • What additional precautions (e.g., maximum number of individuals in elevators, hand washing, use of bathrooms, etc.) will be required based on Brown Policy?
  • Allow ample time / a buffer between research participants’ scheduled visits to ensure multiple participants are not gathering or waiting for their scheduled appointments in the same area.
  • Ensure research team members greeting research participants are prepared to conduct a health screening, if necessary, and are aware of and comfortable with enforcing the requirement that research participants wear a face covering while in any Brown building.

Expectations of Research Participants

  • Complete COVID-19 health screening questions with research personnel prior to coming to campus and an additional health screening on the day of the study visit.
  • Wear a face covering for the study visit. Guidance on appropriate face coverings can be found in Brown’s COVID-19 Face Covering Guidance.
  • Use specified public entrances, most likely the main entrances.
  • Handwashing will be encouraged/required as per study protocols in order to adhere to campus COVID-19 protocols.
  • Research participants must remain in their cars or otherwise remain outside the building until their research study visit is scheduled to begin. 
  • If the research participant requires assistance, only one parent/guardian/support person will be allowed into the building and elevators with the participant.

Health Pre-Screening for Research Participants

A health pre-screening must be conducted with each study participant prior to coming to campus and potentially again, upon arrival, depending on how much time elapses between the pre-screening and study visit.

People with COVID-19 have had a wide range of symptoms reported – ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. People with these symptoms may have COVID-19.

Research participants must be asked if they are experiencing new or worsening signs of possible COVID-19, including:*

  • Fever or chills
  • Cough
  • Shortness of breath or difficulty breathing
  • Fatigue
  • Muscle or body aches
  • Headache
  • New loss of taste or smell
  • Sore throat
  • Congestion or runny nose
  • Nausea or vomiting
  • Diarrhea

*This list does not include all possible symptoms. See the CDC website for more information. 

Research participants affirming any of the above symptoms must be rescheduled. In addition, research participants must be asked if they:

  • Have tested positive as a result of a COVID-19 test.
  • Have been in contact with anyone who has had positive COVID-19 test or someone suspected of having a case of COVID-19 and are currently under quarantine/stay-at-home orders.

If either of the above is endorsed, the research participant’s study visit must be rescheduled.

Script for Use by Research Teams

The Brown HRPP provides this modifiable script to research teams that receive OVPR approval to conduct in-person, on-campus human subjects research activities involving research participants. This script can serve as a verbal script or be converted to an email or a Qualtrics survey for research participants. Please note that this script will be updated over time as the State of Rhode Island enters into new Phases.

Contact Tracing

For studies conducted on-campus during Stage 2, contact tracing logs must include a participant's full name, phone number, location of contact, and date and time of contact, if contact with the participant meets Brown's criteria for contact tracing. Brown's criteria for contact tracing for Stage 2 includes being within 6 feet of someone for a period of time greater than 15 minutes. Per Brown guidance, it is helpful to also document longer contact with others (>30 minutes) when in a Brown research facility even if you maintain at least 6 feet of distance.

For studies where it is expected based on study procedures that participants will meet criteria for inclusion in a Brown contact tracing log, participants must be told how the contact tracing logs will be stored and that the log information will be shared with the Rhode Island Department of Health as required by the State if a COVID-19 exposure occurs. Researchers must maintain contact tracing logs separate from any research data and securely shred the contact logs after 30 days. 

Researchers are welcome to use this Contact Tracing Form for Research Participants. Use of this form is optional.  The modifiable script has also been updated to include information regarding contact tracing.

Required Attestations

There are two circumstances under which Attestations must be submitted to the HRPP:

1) To resume in-person human subjects research activities for international research when you are currently abroad, or to begin a new study abroad where an investigator is already at the study site, regardless of whether Brown is the IRB of record: download the International Research Attestation Form. Please submit this attestation to the HRPP as part of your new IRB Application or IRB Amendment.

2) For any protocol for which Brown has ceded oversight authority to another IRB via an IRB Authorization Agreement (IAA), Principal Investigators must complete an attestation affirming:

  • They will adhere to the requirements of that IRB regarding protection of research participants from COVID-19 related risks; and
  • If any human subjects research activities under an IAA involve in-person interactions with participants on-campus at Brown, they have submitted an exception request for these activities via a plan submitted to the OVPR and will await approval from Brown prior to engaging in these activities.

Click here to download the IAA Attestation. This Attestation should be submitted with your new IRB Application or IRB Amendment and after you have submitted to OVPR your resuming research plan if your plan involves on-campus, in-person research activities at Brown. This Attestation is not required if you have submitted the International Attestation Form for an international study. Please submit this attestation to the HRPP.

Public Readiness and Emergency Preparedness (PREP) Act Declaration

The Secretary of HHS issued a Public Readiness and Emergency Preparedness (PREP) Act Declaration for certain COVID-19 countermeasures on March 10, 2020. In August and September 2020, the FDA and HHS released expanded guidance, allowing Brown to refine the applicability of the COVID-19 countermeasures covered by the Declaration and update the required consent language.

When does the PREP Act not apply?: Brown requires all participants wear an appropriate face covering to protect themselves and those around them when they come to campus. If a participant visits without a face covering or the face covering does not meet Brown requirements, the University will provide them with 3 reusable face coverings. Wearing masks are standard; any risks from them are consistent with everyday life and are not specific to research. 

When does the PREP Act apply?: The PREP Act only applies to Brown research protocols which specifically provide covered countermeasures (i.e. face masks, face shields, gowns) to participants as part of an approved research procedure, instead of allowing participants to use a face mask they may have for personal use. For example, due to the safety protocols at the MRI Research Facility (MRF), participants asked to use the MRI as a research procedure, are required to wear a face mask provided by the MRF that is safe to use in the MRI.

New Consent Form Language for COVID-19 Countermeasures
Human subjects protection regulations require that participants be informed if any of their legal rights are affected, and what recourse is available. To comply with this, Brown University requires that the following additional statement be included in study consent documents.
**As a notethis additional language is unique to COVID-19 countermeasures and does not replace the risks of study procedures that must be included in order for participants to make an informed decision about study participation.

"Due to the coronavirus public health emergency, the U.S. government issued a Declaration under the Public Readiness and Emergency Preparedness (PREP) Act. This Declaration may apply to this study if it involves procedures or other actions that are related to or in response to coronavirus. If it applies, this Declaration limits your right to sue the researchers, healthcare providers, study sponsors, manufacturers, distributors, and potentially others that are involved with this study. However, the U.S. government has a program that may provide compensation to you or your family if you experience serious physical injuries or death related to procedures or other actions taken in this study. To find out more about the 'Countermeasures Injury Compensation Program,' please visit"    


Submission Requirements | Review Priorities | Technology Options for Remote ProceduresFDA Guidance | International Studies | Public Health Surveillance Activities | | Reverting to early Stage(s)

Submission Requirements

Q: If my new IRB Application or Amendment to an existing protocol involves in-person procedures, do I also have to include remote procedure options?

Yes. Any new IRB Application or Amendment submission that involves in-person procedures must include an alternative method(s) to conduct those procedures remotely. If remote conduct of certain procedures (e.g., blood draws) cannot take place remotely, the IRB Application or Amendment must specifically state this.

Building in this flexibility will enable researchers to conduct remote procedures during research ramp-up phases during which in-person contact is not permissible, and seamlessly transition to in-person procedures during later phases when conditions permit without having to submit an amendment to the Brown IRB/HRPP. Importantly, given the unpredictability of the current pandemic, it is possible that researchers may need to revert back to earlier phases that prohibit in-person contact, and this approach will give you the flexibility to do so.

Q: What do I need to include in my IRB Application or Amendment if I am proposing to study COVID-19?

The COVID-19 pandemic affects everyone and those experiences may be situational across participant populations. If you intend to use surveys, interviews, or measures, etc. on or about the effects of COVID-19 as a research procedure, please include the following with your submission:

1) A risk assessment of the impact the questions may have on your study population. This assessment must address if the questions you ask about COVID-19 increase risk for participants beyond the other activities involved in your study. Include this brief assessment in the risk assessment section of your submission form.

2) A list of resources/referrals for participants and a description of how / when the list will be provided to participants. This list must be applicable to the study population and research topic with easily accessible contact information. Some available resources can be found on the COVID-19 Resources page. 

Review Priorities

Q: What are the IRB / HRPP review priorities at this time?

  • The IRB/HRPP is prioritizing Just-in-Time requests and research protocols with external sponsored funding and internal funding awards. Please include "Funded Research" in the subject line of your email submission so we know to prioritize your application in our review queue. 
  • The Office of Research Integrity is also reviewing Plans and Attestations submitted by research teams proposing to resume or modify in-person procedures during Stage 2. Questions about Attestations should be submitted to the main IRB email address.
  • The IRB/HRPP is not prioritizing new IRB applications or amendments in its queue that are limited to in-person international and domestic Brown-sponsored travel. This will continue until the University alters its restrictions on Brown-sponsored travel.

Technology options for remote procedures

Q: What technology options does Brown recommend for the conduct of remote procedures?

If your IRB Application or Amendment involves platforms not already vetted by CIS, then it will take longer to start your research.


Brown CIS and the IRB/HRPP strongly recommend Zoom be used for all remote procedures that involve remote, face-to-face interactions with participants.  This includes administering interventions via video conferencing. Zoom is a CIS-vetted platform and is secure to use for all data risk levels, including Risk Level 3 data.

For studies that wish to use a HIPAA-compliant version of Zoom, please submit a ticket to [email protected] for your request to be authorized. The HIPAA-compliant version of Zoom does not allow for any cloud-based recording. Instead, it will only allow for recording locally, meaning that you must have encryption turned on for the device you will use for recording (i.e., Brown-owned laptop) or saved directly to a Risk Level 3 compliant local server.


Brown CIS and the IRB/HRPP strongly recommend Qualtrics be used for remote data collection procedures. Qualtrics is a CIS-vetted platform and is secure to use for all data risk levels, including Risk Level 3 data. If a Brown investigator has a co-investigator/collaborator at an affiliated site with an instance of REDCaP, it, too may be used for data collection for all data risk levels including Risk Level 3 data.

FDA Guidance

Q: I have an FDA-regulated study. Do I need to report a pause or alteration of research procedures related to COVID-19 to the FDA?

The FDA confirmed that there is no requirement to report to the FDA for now; however, the FDA recommends that if a pause in research extends for a few months or more, the PI may request inactivation so that no annual reports will be necessary. The FDA released more comprehensive guidance that can be found here.

International Studies

Q. I am already at my international study location. May I resume research involving in-person interactions with research participants?

Researchers currently located abroad at their planned study location may resume in-person human subjects research activities if permitted in accordance with country-level and location-specific public health requirements. No exceptions to country requirements will be permitted (i.e., conducting biospecimen collection if social distancing is required).

All researchers who plan to resume in-person human subjects research activities abroad must submit an International Research Attestation Form to the main IRB email address and receive approval prior to commencing those activities. The review and approval process may involve seeking additional information from the PI.

Public Health Surveillance Activities

Q: How do I know if the activities I am proposing are public health surveillance and not human subjects research?

The Revised Common Rule provides the following description of public health surveillance activities that are deemed not to be research (and, therefore, do not require IRB review):

"Public health surveillance activities, including the collection and testing of information or biospecimens, conducted, supported, requested, ordered, required, or authorized by a public health authority. Such activities are limited to those necessary to allow a public health authority to identify, monitor, assess, or investigate potential public health signals, onsets of disease outbreaks, or conditions of public health importance (including trends, signals, risk factors, patterns in diseases, or increases in injuries from using consumer products). Such activities include those associated with providing timely situational awareness and priority setting during the course of an event or crisis that threatens public health (including natural or man-made disasters)."

A "public health authority" means "an agency or authority of the United States, a state, a territory, a political subdivision of a state or territory, an Indian tribe, or a foreign government, or a person or entity acting under a grant of authority from or contract with such public agency, including the employees or agents of such public agency or its contractors or persons or entities to whom it has granted authority, that is responsible for public health matters as part of its official mandate."  The Rhode Island Department of Health, as an example, would meet the definition of a public health authority.

If your proposed activities do not meet the above description and instead the collection of data will be used in whole or in part for research purposes, an IRB Application will be required.

Q: If I am conducting public health surveillance activities, can I still publish?

Yes. A determination that an activity is public health surveillance and not human subjects research has no bearing on your ability to publish your work. 

Q: Are there any special considerations for studies registered on

Yes! As outlined in 42 CFR 11.64(a)(1)(ii), if a protocol is amended in such a manner that changes are communicated to human subjects in the clinical trial, the regulations require that updates to any relevant clinical trial information be submitted not later than 30 calendar days after the protocol amendment is approved by a human subjects protection review board. Additional details can be found in the FAQs.

It remains important to ensure that accurate and up-to-date clinical trial information is available to the public on, particularly for COVID-19 related research. However, due to the potential exceptional impact of this public health emergency on research-related staff availability, NIH acknowledges that delayed updates and corrections may be unavoidable.  Refer to the Top Questions from Responsible Parties Related to COVID-19 for information on specific questions.

NIH will allow late submission of results reporting for recipients covered by the NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information that are unable to submit results reporting information on-time in due to COVID-19. Recipients should notify the funding Institute of Center (IC) of the delay along with documentation of the effects of COVID-19 on the study.

Q: Has consideration been given to how human subjects research activities may be rolled-back or otherwise altered if the State of RI reverts to an earlier Phase or Brown reverts to an earlier Stage?

Yes, careful consideration has been given to ramping down human subjects research activities if the rate of positive cases increases in the State of RI necessitating reverting to an earlier Phase, or if Brown otherwise deems it necessary to revert to an earlier Stage. Given there are more State-level Phases than there are Brown Stages, due consideration has similarly been given to activities approved in Brown's Stage 2, that may be permitted to continue if the State-level Phase is rolled back, but local conditions do not require Brown to revert to its Stage 1. Importantly, there is active, ongoing monitoring of both State-level conditions and local, Brown-campus based conditions, all intended to prioritize the health and welfare of Brown researchers and volunteer research participants. 


Need assistance with preparing a new IRB protocol or an amendment? Determining if a proposed project requires IRB review? Applying IRB-related policies or procedures?

Contact an appropriate HRPP team member to set up a time to discuss.

Learn more about the centralized submission, review, negotiation and approval process for Data Use Agreements here!


Did you know about NIH's New Funding Opportunities for Basic Experimental Studies Involving Humans? Read more here.